DHR vs PFE
Danaher · Pfizer
| DHR Danaher Healthcare | PFE Pfizer Healthcare | |
|---|---|---|
| Market | ||
| Price | $232.23 -2.00% | $30.52 +1.90% |
| Market cap | $163.4B | $174.0B |
| P/E (TTM) | 37.7 | 40.1 |
| Dividend yield | 0.49% | 5.38% |
| 52-week range | $160.93 – $242.80 | $23.62 – $30.67 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Danaher (DHR): Core Sales Up 3% And Adjusted EPS Up 11.5%, But A Tax Swing Was 81% Of The… Nov 1, 2026 | Pfizer's Vyndaqel Patent Cliff Just Got Pushed To 2031 — The Market Hasn't Noticed Yet (P… Jun 14, 2026 |
| Latest earnings | ||
| Reported | Oct 21, 2026 | — |
| Revenue | $6.6 billion +8.5% YoY | — |
| EPS | — | — |
| Guidance | Guidance revised | — |
| Revenue growth, last 4 reports | +8.5% | — |
| Topics | ||
| Main topics | ||
| Company page · Earnings releases | Company page | |
Shared topics: Mergers & Acquisitions
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.